日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FOXJ1 mediates taxane resistance through regulation of microtubule dynamics.

FOXJ1 通过调节微管动力学介导紫杉烷类药物耐药性。

Xie Fang, Gjyrezi Ada, Fein Daniel, Labaf Maryam, Poluben Larysa, Ersoy-Fazlioglu Betul, Dennehy Christopher M, Voznesensky Olga, Gad Aniket, Corey Eva, Varkaris Andreas, Einstein David J, Bhatt Rupal S, Giannakakou Paraskevi, Balk Steven P

Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer

DLL3靶向T细胞衔接剂MK-6070在神经内分泌前列腺癌中的临床前活性

Ku, Sheng-Yu; Manzar, Nishat; Garcia, Maria Mica; Kim, Min Jin; Einstein, David J; Balk, Steven P; Yamada, Yasutaka; Beltran, Himisha

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.

靶向 BCL-XL 的 BH3 模拟物对 RB1 缺失和复制压力的实体瘤有效

Varkaris Andreas, Wang Keshan, Nouri Mannan, Kozlova Nina, Schmidt Daniel R, Stavridi Anastasia, Arai Seiji, Ambrosio Nicholas, Poluben Larysa, Jimenez-Vacas Juan M, Westaby Daniel, Carmichael Juliet, Xie Fang, Figueiredo Ines, Buroni Lorenzo, Neeb Antje, Gurel Bora, Chevalier Nicholas, Brown Lisha, Voznesensky Olga, Chen Shao-Yong, Russo Joshua W, Yuan Xin, Juric Dejan, Beltran Himisha, De Bono Johann S, Vander Heiden Matthew G, Einstein David J, Muranen Taru, Corey Eva, Sharp Adam, Balk Steven P

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.

在具有 TMPRSS2:ERG 融合的前列腺癌中,雄激素剥夺介导的 AKT 激活增强。

Ma Fen, Chen Sen, Cecchi Luigi, Ersoy-Fazlioglu Betul, Russo Joshua W, Arai Seiji, Awad Seifeldin, Calagua Carla, Xie Fang, Poluben Larysa, Voznesensky Olga, Ku Anson T, Karzai Fatima, Cai Changmeng, Einstein David J, Ye Huihui, Yuan Xin, Toker Alex, Taplin Mary-Ellen, Sowalsky Adam G, Balk Steven P

Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of life

转移性去势抵抗性前列腺癌患者在生命最后一年接受医疗保健服务的天数

Sentana-Lledo, Daniel; Barnett, Amelia; Einstein, David J; Gupta, Arjun; Morgans, Alicia K

Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol

通过多组分运动疗法打破转移性前列腺癌患者的虚弱-肌肉减少症-雄激素剥夺疗法(ADT)轴:FIERCE试验方案

Wilson, Rebekah L; Vulczak, Anderson; Morgans, Alicia K; Norris, Mary; Greer, Jocelyn; Votta, Jennie; Vamvini, Maria; Einstein, David J; Uno, Hajime; Rosenthal, Michael; Vander Heiden, Matthew G; Dieli-Conwright, Christina M

Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma

融合驱动的致癌程序塑造了易位性肾细胞癌的免疫图谱

Konda, Prathyusha; Weiss, Cary N; Cui, Yantong; Matar, Sayed; Wang, Jinyu; Nabil, Yasmin L; Deodhar, Riva; Li, Jiao; Horst, Jack; Camp, Sabrina Y; Sheshdeh, Aseman B; Hecht, Jonathan L; Einstein, David J; Rustagi, Yashika; Nag, Anwesha; Thorner, Aaron R; Zhang, Cheng-Zhong; Van Allen, Eliezer M; Signoretti, Sabina; Choueiri, Toni K; Viswanathan, Srinivas R

A genetic basis for sex differences in Xp11 translocation renal cell carcinoma

Xp11易位肾细胞癌性别差异的遗传基础

Achom, Mingkee; Sadagopan, Ananthan; Bao, Chunyang; McBride, Fiona; Li, Jiao; Konda, Prathyusha; Tourdot, Richard W; Xu, Qingru; Nakhoul, Maria; Gallant, Daniel S; Ahmed, Usman Ali; O'Toole, Jillian; Freeman, Dory; Lee, Gwo-Shu Mary; Hecht, Jonathan L; Kauffman, Eric C; Einstein, David J; Choueiri, Toni K; Zhang, Cheng-Zhong; Viswanathan, Srinivas R

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial

生化复发性前列腺癌患者的无转移生存期与无治疗生存期:EMBARK试验

Einstein, David J; Regan, Meredith M; Stevens, Julia S; McDermott, David F; Madan, Ravi A

Reply to B. Tombal et al

回复 B. Tombal 等人

Einstein, David J; Regan, Meredith M; Stevens, Julia S; McDermott, David F; Madan, Ravi A